MA27153A1 - Formulations pharmaceutiques de derives de platine - Google Patents

Formulations pharmaceutiques de derives de platine

Info

Publication number
MA27153A1
MA27153A1 MA27715A MA27715A MA27153A1 MA 27153 A1 MA27153 A1 MA 27153A1 MA 27715 A MA27715 A MA 27715A MA 27715 A MA27715 A MA 27715A MA 27153 A1 MA27153 A1 MA 27153A1
Authority
MA
Morocco
Prior art keywords
formulations
pharmaceutical formulations
platinum derivatives
pharmaceutically acceptable
present
Prior art date
Application number
MA27715A
Other languages
English (en)
Inventor
Sara Lauria
Cristina Ciocca
Alessandro Martini
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21744006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27153(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of MA27153A1 publication Critical patent/MA27153A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

DEPOSANT Société dite: PHARMACIA ITALIA S.P.A. REVENDICATION DE PRIORITES US 6 Décembre 2001 10/010,122 Voir en annexe le titre de l'invention et le texte de l'abrégé Formulations pharmaceutiques de dérivés de platine La présente invention concerne des formulations de solutions stables nouvelles comprenant de l'oxaliplatine, une quantité stabilisante efficace d'acide lactique et/ou d'un de ses sels pharmaceutiquement acceptables et un support pharmaceutiquement acceptable. Un procédé pour la production de telles formulations prêtes à l'administration et une méthode pour leur utilisation en thérapie antitumorale sont également inclus dans le cadre de la présente invention.
MA27715A 2001-12-06 2004-06-04 Formulations pharmaceutiques de derives de platine MA27153A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/010,122 US6476068B1 (en) 2001-12-06 2001-12-06 Platinum derivative pharmaceutical formulations

Publications (1)

Publication Number Publication Date
MA27153A1 true MA27153A1 (fr) 2005-01-03

Family

ID=21744006

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27715A MA27153A1 (fr) 2001-12-06 2004-06-04 Formulations pharmaceutiques de derives de platine

Country Status (42)

Country Link
US (3) US6476068B1 (fr)
EP (1) EP1453517B1 (fr)
JP (1) JP2005515202A (fr)
KR (1) KR100941210B1 (fr)
CN (1) CN100540006C (fr)
AP (1) AP1760A (fr)
AR (1) AR037629A1 (fr)
AT (1) ATE317260T1 (fr)
AU (1) AU2002352105B2 (fr)
BR (1) BR0214757A (fr)
CA (1) CA2468916C (fr)
CO (1) CO5580776A2 (fr)
CR (1) CR7362A (fr)
CY (1) CY1105608T1 (fr)
DE (1) DE60209145T2 (fr)
DK (1) DK1453517T3 (fr)
EA (1) EA008090B1 (fr)
EC (1) ECSP045140A (fr)
ES (1) ES2258661T3 (fr)
GE (1) GEP20063895B (fr)
HK (1) HK1072002A1 (fr)
HR (1) HRP20040514A2 (fr)
HU (1) HUP0402217A3 (fr)
IL (2) IL162348A0 (fr)
IS (1) IS2580B (fr)
MA (1) MA27153A1 (fr)
ME (1) MEP10408A (fr)
MX (1) MXPA04005423A (fr)
MY (1) MY134422A (fr)
NO (1) NO330159B1 (fr)
NZ (1) NZ533383A (fr)
OA (1) OA12739A (fr)
PL (1) PL206755B1 (fr)
PT (1) PT1453517E (fr)
RO (1) RO121509B1 (fr)
RS (1) RS50360B (fr)
SI (1) SI21493A (fr)
TN (1) TNSN04104A1 (fr)
TW (1) TW200409640A (fr)
UA (1) UA77728C2 (fr)
WO (1) WO2003047587A1 (fr)
ZA (1) ZA200404525B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1404689A1 (fr) * 2001-07-02 2004-04-07 Debiopharm S.A. Substance active a base d'oxaliplatine presentant une faible teneur en acide oxalique
CA2388352A1 (fr) * 2002-05-31 2003-11-30 Voiceage Corporation Methode et dispositif pour l'amelioration selective en frequence de la hauteur de la parole synthetisee
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
DE10314377A1 (de) * 2003-03-28 2004-10-07 Stada Arzneimittel Ag Gebrauchsfertige Oxaliplatin-Lösungen
GB2441445B (en) * 2003-08-28 2008-04-23 Mayne Pharma Ltd Acid containing oxaliplatin formulation
NZ545591A (en) * 2003-08-28 2008-11-28 Mayne Pharma Ltd Acid containing oxaliplatin formulations
CA2543820C (fr) * 2003-11-07 2012-07-10 Chiron Corporation Methodes de synthese de composes de quinolinone
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
RS52668B (en) * 2004-06-09 2013-06-28 Taiho Pharmaceutical Co. Ltd. ANTITUMOR EFFECT, ANTI-TUMOR AND ANALYSIS PROCESS
US7208616B2 (en) * 2004-07-12 2007-04-24 Sicor, Inc. Cis-diiodo-(trans-L-1,2-cyclohexanediamine) platinum (II) complex and processes for preparing high purity oxaliplatin
US20060063720A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Oxaliplatin solution concentrate
US20060063833A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Ready-to-use oxaliplatin solutions
DE102004052877B4 (de) * 2004-11-02 2008-06-19 Ebewe Pharma Ges.M.B.H. Nfg.Kg Stabile wässrige Formulierungen eines Platin-Derivats
CN1311818C (zh) * 2004-11-22 2007-04-25 山东蓝金生物工程有限公司 一种抗实体肿瘤的药物组合物
DE102004063764A1 (de) * 2004-12-29 2006-07-13 Hexal Ag Kunststoff-Flasche für Oxaliplatin
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
ATE430564T1 (de) * 2005-03-28 2009-05-15 Dabur Pharma Ltd Stabile pharmazeutische zusammensetzungen aus antitumoralen platin-(ii)-mitteln
KR101319122B1 (ko) * 2005-05-13 2013-10-23 노파르티스 아게 약물 저항성 암을 치료하는 방법
DE102005038347A1 (de) * 2005-08-11 2007-02-15 Hexal Ag Herstellung einer Oxaliplatin-Lösung und Behälter sowie Behälter-Set mit der Lösung
WO2007029268A2 (fr) * 2005-09-05 2007-03-15 Dabur Pharma Limited Formulation stable d'oxaliplatine
PL1957074T3 (pl) * 2005-11-29 2014-08-29 Novartis Ag Preparaty chinolinonów
US20090076139A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched oxalplatin
WO2009087660A1 (fr) 2007-11-12 2009-07-16 Intas Pharmaceuticals Limited Composition d'oxaliplatine stable pour une administration parentérale
US20090221622A1 (en) * 2008-02-29 2009-09-03 Eagle Pharmaceuticals, Inc. Topotecan ready to use solutions
WO2010056847A2 (fr) * 2008-11-13 2010-05-20 Taigen Biotechnology Co., Ltd. Formule lyophilisée
WO2011034394A2 (fr) 2009-09-21 2011-03-24 주식회사 중외제약 Nanoparticules d'oxaliplatine et leur procédé de préparation
US9387152B2 (en) 2010-06-28 2016-07-12 The General Hospital Corporation Blood substitutes and uses thereof
CN102274171A (zh) * 2011-08-04 2011-12-14 上海希迪制药有限公司 一种奥沙利铂注射剂
MX363455B (es) 2012-07-18 2019-03-25 Onyx Therapeutics Inc Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
JP5929607B2 (ja) * 2012-08-06 2016-06-08 ニプロ株式会社 オキサリプラチン製剤
CN102885765B (zh) * 2012-10-25 2013-11-06 哈药集团生物工程有限公司 一种盐酸伊立替康注射液及其制备方法
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
KR101683635B1 (ko) * 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
CN109069342A (zh) 2016-02-09 2018-12-21 太阳医药工业有限公司 灌注系统
US11339209B2 (en) 2016-11-14 2022-05-24 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
MX2020007462A (es) 2018-01-12 2020-09-14 Metimedi Pharmaceuticals Co Ltd Metodos de tratamiento de enfermedades inflamatorias cronicas.
KR101998246B1 (ko) 2018-08-22 2019-07-10 주식회사 메타파인즈 금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US5041578A (en) * 1988-11-22 1991-08-20 Board Of Regents, The University Of Texas System Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
ATE247471T1 (de) 1991-11-15 2003-09-15 Smithkline Beecham Corp Cisplatin und topotecan enthaltende zusammensetzung als antitumor.
JPH0776230B2 (ja) 1992-01-13 1995-08-16 田中貴金属工業株式会社 白金化合物の製造方法
JPH06287021A (ja) 1992-04-22 1994-10-11 Tanaka Kikinzoku Kogyo Kk 光学活性な白金錯化合物の光学的分割方法
JP2673331B2 (ja) 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
WO1994012193A1 (fr) 1992-11-24 1994-06-09 Debiopharm S.A. Combinaison de cisplatine avec l'oxaliplatine
CA2308082A1 (fr) * 1992-11-27 1994-06-09 Paul Handreck Composition injectable
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
UA42779C2 (uk) 1994-08-08 2001-11-15 Дебіофарм С.А. Фармацевтично стійкий препарат оксалату платини для парентерального застосування
EP0715854B1 (fr) 1994-11-11 2003-09-10 Debiopharm S.A. Compositions carcinostatiques contenant du cis-oxaliplatine et un ou plusieurs autres carcinostatiques
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
AU4842996A (en) * 1995-02-28 1996-09-18 Yoshinori Kidani Novel platinum (iv) complexes, process for producing the same, and carcinostatic agents containing the same
US5776959A (en) 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
EP0897389B1 (fr) * 1996-03-11 2002-07-03 Yoshinori Kidani Complexes de platine dinucleaires, procede pour leur preparation et compositions pharmaceutiques en contenant
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
EP0929293B1 (fr) 1996-08-23 2003-10-22 Sequus Pharmaceuticals, Inc. Liposomes contenant un compose cisplatine
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
NZ337502A (en) 1997-02-05 2001-02-23 Upjohn Co Lipid complexes and liposomes of highly insoluble platinum complexes
ATE338553T1 (de) 1997-03-07 2006-09-15 Sanofi Aventis Us Llc Antitumorkombination aus 3-amino-1,2,4- benzotriazine 1,4-dioxid/paclitaxel/platin
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
GB9804013D0 (en) * 1998-02-25 1998-04-22 Sanofi Sa Formulations
PT1121117E (pt) 1998-10-14 2002-10-31 Debiopharm Sa Acondicionamento de uma preparacao de oxaliplatina
DE60005376T2 (de) 1999-08-30 2004-07-01 Debiopharm S.A. Oxaliplatinhaltige parenteral anzuwendende stabilisierte arzneizubereitung und verfahren zu deren herstellung
WO2001066102A2 (fr) 2000-03-08 2001-09-13 Bristol-Myers Squibb Company Forme posologique orale d'administration de la combinaison de tegafur, uracile, acide folique et oxaliplatine et procede d'utilisation correspondant
SE0003026D0 (sv) * 2000-08-25 2000-08-25 Kerstin Sunnerheim Use for conifer sapling protection

Also Published As

Publication number Publication date
CA2468916C (fr) 2009-01-20
CN1612737A (zh) 2005-05-04
TNSN04104A1 (fr) 2006-06-01
OA12739A (en) 2006-06-30
US20030109514A1 (en) 2003-06-12
RO121509B1 (ro) 2007-10-30
SI21493A (sl) 2004-12-31
DE60209145D1 (de) 2006-04-20
CY1105608T1 (el) 2010-12-22
PL206755B1 (pl) 2010-09-30
PT1453517E (pt) 2006-06-30
AR037629A1 (es) 2004-11-17
KR20050058278A (ko) 2005-06-16
RS50360B (sr) 2009-11-10
IL162348A0 (en) 2005-11-20
US20030109515A1 (en) 2003-06-12
US6476068B1 (en) 2002-11-05
HUP0402217A3 (en) 2005-11-28
ATE317260T1 (de) 2006-02-15
MXPA04005423A (es) 2004-10-11
AU2002352105A1 (en) 2003-06-17
DK1453517T3 (da) 2006-06-19
HUP0402217A2 (hu) 2005-01-28
EA200400777A1 (ru) 2004-12-30
ES2258661T3 (es) 2006-09-01
NZ533383A (en) 2007-02-23
IL162348A (en) 2010-11-30
KR100941210B1 (ko) 2010-02-10
ZA200404525B (en) 2005-08-15
IS7298A (is) 2004-06-03
JP2005515202A (ja) 2005-05-26
DE60209145T2 (de) 2006-10-26
AP1760A (en) 2007-07-18
YU59704A (sh) 2006-08-17
CN100540006C (zh) 2009-09-16
CA2468916A1 (fr) 2003-06-12
AP2004003055A0 (en) 2004-06-30
AU2002352105B2 (en) 2009-12-03
US6673805B2 (en) 2004-01-06
EP1453517B1 (fr) 2006-02-08
UA77728C2 (en) 2007-01-15
CR7362A (es) 2009-02-12
EP1453517A1 (fr) 2004-09-08
ECSP045140A (es) 2004-08-27
MY134422A (en) 2007-12-31
EA008090B1 (ru) 2007-02-27
WO2003047587A1 (fr) 2003-06-12
HK1072002A1 (en) 2005-08-12
NO330159B1 (no) 2011-02-28
PL370254A1 (en) 2005-05-16
TW200409640A (en) 2004-06-16
HRP20040514A2 (en) 2004-10-31
MEP10408A (en) 2011-02-10
CO5580776A2 (es) 2005-11-30
GEP20063895B (en) 2006-08-10
IS2580B (is) 2010-02-15
BR0214757A (pt) 2004-09-14
NO20042842L (no) 2004-07-05

Similar Documents

Publication Publication Date Title
MA27153A1 (fr) Formulations pharmaceutiques de derives de platine
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
SE0300010D0 (sv) Novel Compounds
NO20022264D0 (no) Farmasöytisk blanding inneholdende tolterodin, samt anvendelse derav
ES2160640T3 (es) Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos.
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
MA27596A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
MY143795A (en) Tetrahydropyridoindole derivatives
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
SE9900961D0 (sv) Novel compounds
SE0102440D0 (sv) New compound
HUP0004780A2 (hu) Prosztaglandin agonisták felhasználása merevedési rendellenességek vagy impotencia kezelésében
HK1046637A1 (en) Use of racemic alpha-lipoic acid in preparation pharmaceutical for treatment of migraine.
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
SE9900190D0 (sv) New compounds
SE0203817D0 (sv) New composition
NO20001812L (no) Gallesyresalter av metaller med fysiologisk virkning, samt terapeutisk anvendelse derav
IT1306186B1 (it) Sali non igroscopici di principi attivi ad attivita' terapeutica e/onutrizionale e composizioni atte alla somministrazione orale
NO940064L (no) Öyepreparat på polyakrylsyrebasis